Molecular Partners Ag (MOLN) Profit After Tax (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Profit After Tax of -$16784.9 for Q1 2026, up 10.02% year-on-year from -$15256.6 in Q1 2025, and up 99.98% on a QoQ basis from -$77.1 million in Q4 2025.
Molecular Partners Ag (MOLN) Profit After Tax (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Profit After Tax for 7 consecutive years, with -$16784.9 the latest figure, recorded in Q1 2026.
- Quarterly Profit After Tax rose 10.02% year-over-year to -$16784.9 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$77.2 million (down 214.24% YoY) and the FY2025 annual result came in at -$77.2 million, down 214.23% from the prior year.
- Profit After Tax grew to -$16784.9 in Q1 2026 per MOLN's latest filing, from -$77.1 million in the prior quarter.
- Over the last five years, Profit After Tax for MOLN reached as high as $122.2 million in Q4 2022 and fell as low as -$77.1 million in Q4 2025.
- A 5-year average of $1.2 million and a median of -$16677.6 in 2024 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2022 — Profit After Tax surged 1020.39% — and 2023, when it sank 278.7%.
- Year by year, Profit After Tax stood at $122.2 million in 2022, then slumped by 157.15% to -$69.8 million in 2023, then jumped by 196.85% to $67.6 million in 2024, then plunged by 214.06% to -$77.1 million in 2025, then soared by 99.98% to -$16784.9 in 2026.
- According to Business Quant data, Profit After Tax over the past three periods registered -$16784.9, -$77.1 million, and -$15258.8 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | -16,784.95 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16,784.95 |
| Dec 31, 2025 | -77.14 Mn |
| Sep 30, 2025 | -15,258.84 |
| Jun 30, 2025 | -27,182.36 |
| Mar 31, 2025 | -18,653.55 |
| Dec 31, 2024 | 67.63 Mn |
| Sep 30, 2024 | -20,607.22 |
| Jun 30, 2024 | -16,677.58 |
| Mar 31, 2024 | -12,974.85 |
| Dec 31, 2023 | -69.83 Mn |
| Sep 30, 2023 | -12,950.69 |
| Jun 30, 2023 | -17.78 Mn |
| Mar 31, 2023 | -15,977.42 |
| Dec 31, 2022 | 122.19 Mn |
| Sep 30, 2022 | -15,424.16 |
| Jun 30, 2022 | -4.70 Mn |
| Mar 31, 2022 | 168,520.72 |
| Dec 31, 2021 | -69.13 Mn |
| Sep 30, 2021 | -13,406.09 |
| Jun 30, 2021 | -36.79 Mn |